What Is Lumvoa Used For?

Key Takeaways

• Lumvoa (veligrotug) is a new prescription medicine used to treat thyroid eye disease (TED), an autoimmune condition that causes swelling around the eyes.
• The U.S. Food and Drug Administration (FDA) approved Lumvoa in June 2026 for both active TED and chronic (long-term) TED.
• Lumvoa is designed to calm the inflammation behind the eyes, and in studies it reduced eye bulging and double vision for many patients.
• A full course is five IV (intravenous) infusions given three weeks apart, finishing in about 12 weeks.
• Bay Area Rheumatology is a leading arthritis and autoimmune care clinic in the Tampa Bay area, providing infusion therapy for thyroid eye disease at its Clearwater and Oldsmar offices. Request an appointment with Bay Area Rheumatology to ask whether Lumvoa may be right for you.

APPOINTMENTS

What Condition Is Lumvoa Approved to Treat?

Lumvoa is approved to treat thyroid eye disease. TED happens when the immune system attacks the muscle and fat tissue around the eyes, causing swelling, inflammation, and a buildup of tissue. It is most common in people with Graves’ disease, an autoimmune condition that makes the thyroid overactive.

The FDA approved Lumvoa on June 26, 2026, for both active and chronic TED, according to the Graves’ Disease and Thyroid Foundation’s Lumvoa approval announcement. Active TED is the early phase, when inflammation is still changing the eyes. Chronic TED is the later, longer-lasting phase. That means Lumvoa may be an option both for people with newer symptoms and for those who have lived with TED for years.

Which TED Symptoms Does Lumvoa Target?

Lumvoa was studied for its effect on two of the most bothersome TED symptoms:

• Eye bulging, also called proptosis.
• Double vision, also called diplopia.

According to the Lumvoa clinical study results, measured at 15 weeks:

A placebo is an infusion with no medicine in it, used for comparison. Some people in the studies saw less eye bulging as early as three weeks into treatment.

What Kind of Medicine Is Lumvoa?

Lumvoa is a biologic, which is a medicine made from living cells. It belongs to a group called insulin-like growth factor-1 receptor (IGF-1R) inhibitors. In simple terms, it is designed to block signals on cells that help drive the swelling and tissue changes of TED. The exact way it works is not yet fully understood.

How Lumvoa Differs From Tepezza

Before Lumvoa, Tepezza (teprotumumab) was the main medicine approved specifically for TED. Both are given by IV infusion, but their schedules differ. Here is how they compare:

Sources: Graves’ Disease and Thyroid Foundation and the FDA Drug Trial Snapshot for Tepezza

Lumvoa’s first infusion takes about 45 minutes. If you tolerate it well, the remaining infusions take about 30 minutes each. Your care team will weigh your symptoms, health history, and goals to decide which option fits you best.

Where Lumvoa Fits Into a Broader TED Treatment Plan

Lumvoa is usually one part of a larger plan. Many people with TED also benefit from:

• Thyroid care to keep hormone levels in a healthy range.
• Supportive eye care, such as eye drops for dryness or prism glasses for double vision.
• Quitting smoking, which your care team may recommend to help protect your eyes.
• Surgery after the disease is stable, if lasting changes remain.

Because TED can affect comfort, vision, and appearance, care often involves a team of providers working together.

TED Infusion Therapy in Tampa Bay at Bay Area Rheumatology

Bay Area Rheumatology provides infusion therapy for thyroid eye disease in state-of-the-art infusion suites at both its Clearwater and Oldsmar offices. The team works alongside your referring provider and helps secure insurance approvals for your treatment. Learn more on the Bay Area Rheumatology infusion therapy page.

What Questions to Ask Before Starting Lumvoa

Before your first infusion, talk with your care team about your full health picture. Helpful questions include:

• Do I have diabetes or high blood sugar? Lumvoa can raise blood sugar, so your levels should be under control before and during treatment.
• Do I have inflammatory bowel disease (IBD)? Lumvoa may make IBD conditions like Crohn’s disease or ulcerative colitis worse.
• Am I pregnant or planning a pregnancy? Lumvoa may harm an unborn baby. Women who can become pregnant should use effective birth control before, during, and for six months after the final dose.
• How will my hearing be checked? Lumvoa may cause hearing problems, and in some cases hearing loss may be permanent. Your hearing should be checked before, during, and after treatment.
• What other medicines or supplements do I take?
• Will my insurance cover Lumvoa? Bay Area Rheumatology’s team can help with prior authorization. You can also review the Bay Area Rheumatology today.

Ask Bay Area Rheumatology Whether Lumvoa Fits Your TED Plan

Lumvoa is a new, shorter-course treatment for thyroid eye disease that may ease eye bulging and double vision, whether your TED is new or long-standing. Bay Area Rheumatology provides closely monitored infusion care for patients with thyroid eye disease throughout Tampa Bay. To find out whether this treatment fits your needs, request an appointment with Bay Area Rheumatology to discuss thyroid eye disease infusion therapy at the Clearwater or Oldsmar office.

Appointments

Frequently Asked Questions